AU2021307553A1 - APC targeting units for immunotherapy - Google Patents

APC targeting units for immunotherapy Download PDF

Info

Publication number
AU2021307553A1
AU2021307553A1 AU2021307553A AU2021307553A AU2021307553A1 AU 2021307553 A1 AU2021307553 A1 AU 2021307553A1 AU 2021307553 A AU2021307553 A AU 2021307553A AU 2021307553 A AU2021307553 A AU 2021307553A AU 2021307553 A1 AU2021307553 A1 AU 2021307553A1
Authority
AU
Australia
Prior art keywords
fusion polypeptide
sequence
unit
targeting
route
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021307553A
Other languages
English (en)
Inventor
Marina Barrio CALVO
Stine FRIIS
Jens KRINGELUM
Birgitte RØNØ
Anders Bundgaard SØRENSEN
Christian THYGESEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evaxion Biotech AS
Original Assignee
Evaxion Biotech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evaxion Biotech AS filed Critical Evaxion Biotech AS
Publication of AU2021307553A1 publication Critical patent/AU2021307553A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001121—Receptors for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021307553A 2020-07-14 2021-07-14 APC targeting units for immunotherapy Pending AU2021307553A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20185743.0 2020-07-14
EP20185743 2020-07-14
EP20207526 2020-11-13
EP20207526.3 2020-11-13
EP21171319 2021-04-29
EP21171319.3 2021-04-29
PCT/EP2021/069582 WO2022013277A1 (en) 2020-07-14 2021-07-14 Apc targeting units for immunotherapy

Publications (1)

Publication Number Publication Date
AU2021307553A1 true AU2021307553A1 (en) 2023-02-16

Family

ID=79555093

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021307553A Pending AU2021307553A1 (en) 2020-07-14 2021-07-14 APC targeting units for immunotherapy

Country Status (6)

Country Link
US (1) US20230355733A1 (https=)
EP (1) EP4181949A1 (https=)
JP (1) JP2023533871A (https=)
AU (1) AU2021307553A1 (https=)
CA (1) CA3183951A1 (https=)
WO (1) WO2022013277A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023023260A2 (pt) 2021-05-10 2024-01-30 Nykode Therapeutics ASA Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica
US20250304626A1 (en) 2021-05-26 2025-10-02 Evaxion Biotech A/S Vaccination targeting intracellular pathogens
CN114106207B (zh) * 2022-01-24 2022-04-26 诺未科技（北京）有限公司 Ccl5的用途
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1503793A2 (en) * 2002-05-10 2005-02-09 Inex Pharmaceuticals Corp. Cancer vaccines and methods of using the same
AU2013224658A1 (en) * 2006-07-21 2013-09-19 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
JP2013532971A (ja) * 2010-06-25 2013-08-22 バッシボディ アクスイェ セルスカプ ホモ二量体タンパク質コンストラクト
AU2012311238A1 (en) * 2011-09-23 2014-04-17 University Of Oslo Vaccibodies targeted to cross-presenting dendritic cells
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
IL260030B2 (en) * 2016-01-08 2025-12-01 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
US20180161412A1 (en) * 2016-12-14 2018-06-14 Cyvax, Inc. Extended protection protein vaccines against infectious agents
CA3060569A1 (en) 2017-04-19 2018-10-25 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
WO2018201017A1 (en) * 2017-04-27 2018-11-01 Washington University Dendritic cell targeted adenovirus for vaccination
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
CN113423419A (zh) * 2019-01-04 2021-09-21 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
US20230147574A1 (en) * 2020-04-07 2023-05-11 Evaxion Biotech A/S Neoepitope immunotherapy with APC targeting unit

Also Published As

Publication number Publication date
US20230355733A1 (en) 2023-11-09
WO2022013277A1 (en) 2022-01-20
CA3183951A1 (en) 2022-01-20
JP2023533871A (ja) 2023-08-04
EP4181949A1 (en) 2023-05-24

Similar Documents

Publication Publication Date Title
JP7535489B2 (ja) 治療用抗癌ネオエピトープワクチン
US20230355733A1 (en) APC targeting units for immunotherapy
Liu et al. DNA vaccines: recent developments and future possibilities
AU2020234003B2 (en) Nucleic acid vaccination using neo-epitope encoding constructs
US9885017B2 (en) Compositions and methods to immunize against hepatitis C virus
CN111148533A (zh) 用于嵌合抗原受体t细胞疗法的组合物及其用途
US20150056227A1 (en) Priming of an immune response
CN109045289A (zh) 疫苗接种和抑制pd-1途径的组合
WO2021204911A1 (en) Neoepitope immunotherapy with apc targeting unit
ES3035198T3 (en) Cpg amphiphiles and uses thereof
AU2019351458A1 (en) Immunity-inducing agent comprising antigen peptide-adjuvant nucleotide conjugate and pharmaceutical composition comprising same
US20230072079A1 (en) Nucleic acid vaccination using neo-epitope encoding constructs
Lemieux Technological advances to increase immunogenicity of DNA vaccines
Babiuk et al. DNA vaccination: a simple concept with challenges regarding implementation
Schmidt et al. MIDGE vectors and dSLIM immunomodulators: DNA-based molecules for gene therapeutic strategies
Du et al. The rise of mRNA therapeutic vaccines
Benvenuti et al. Genetic vaccination for the immunotherapy of B-cell malignancies
CN116457006A (zh) 用于免疫疗法的apc靶向单元
NON CHAPTER FIVE CHARACTERIZATION OF SPLP AND LN CpG-ODN AS A NON-VIRAL GENETIC CANCER VACCINE4
Mackiewicz Workshop U Vaccination and Immunopharmacology
HK40026581A (en) Compositions for chimeric antigen receptor t cell therapy and uses thereof
JP2012523456A (ja) 細胞内ポリヌクレオチド結合タンパク質を発現するベクターの、アジュバントとしての使用
ES2330182A1 (es) Vacuna contra el virus de papiloma humano.